Breo Ellipta vs Trelegy Ellipta
Side-by-side cost comparison based on Medicare Part D data
Breo Ellipta
Fluticasone/Vilanterol
Manufactured by GlaxoSmithKline
Trelegy Ellipta
Fluticasone/Umeclidinium/Vilanterol
Manufactured by GlaxoSmithKline
Breo Ellipta costs 42% less per claim than Trelegy Ellipta ($221.00 vs $380.00). A generic version of Breo Ellipta is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Breo Ellipta | Trelegy Ellipta |
|---|---|---|
| Avg Cost Per Claim | $221.00 | $380.00 |
| Total Medicare Spending | $1.2B | $2.9B |
| Total Beneficiaries | 680,000 | 865,000 |
| Total Claims | 5,240,000 | 7,560,000 |
| Annual Cost/Patient | $1,700.00 | $3,325.00 |
| Year-over-Year Change | -4.3% | +19.8% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Sep 26, 2030 |
| Manufacturer | GlaxoSmithKline | GlaxoSmithKline |
| Condition | Asthma/COPD | Asthma/COPD |
| Generic Name | Fluticasone/Vilanterol | Fluticasone/Umeclidinium/Vilanterol |
Breo Ellipta vs Trelegy Ellipta: What the Data Shows
Breo Ellipta (Fluticasone/Vilanterol) and Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol) are both used to treat asthma/copd. Based on Medicare Part D data, Breo Ellipta costs $221.00 per claim, which is 42% less than Trelegy Ellipta at $380.00 per claim.
Medicare spent $1.2B on Breo Ellipta and $2.9B on Trelegy Ellipta. In terms of patient reach, Trelegy Ellipta serves more beneficiaries (865,000 vs 680,000).
Year-over-year spending changed -4.3% for Breo Ellipta and +19.8% for Trelegy Ellipta. Trelegy Ellipta saw significant spending growth, suggesting increased utilization or price increases.
Breo Ellipta has a generic available, while Trelegy Ellipta remains brand-only until its patent expires Sep 26, 2030.
Frequently Asked Questions
Breo Ellipta is cheaper at $221.00 per claim, compared to $380.00 for Trelegy Ellipta. That makes Breo Ellipta about 42% less expensive per claim based on Medicare Part D data.
Yes, both Breo Ellipta and Trelegy Ellipta are used to treat asthma/copd. Your doctor can help determine which medication is more appropriate for your specific situation.
Breo Ellipta has a generic version (Fluticasone/Vilanterol) available, which is typically much cheaper. Trelegy Ellipta is currently brand-only, with patent expiring Sep 26, 2030.
Medicare Part D spent $1.2B on Breo Ellipta covering 680,000 beneficiaries, and $2.9B on Trelegy Ellipta covering 865,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.